Skip to content
No results
  • About Us
  • Contact Us
  • Disclaimer
  • Event Venues
  • Events and Conferences
  • Home
  • Organizer Dashboard
  • Organizer Dashboard
  • Privacy Policy
  • Submit Organizer Form
  • Submit Organizer Form
  • Submit Venue Form
  • Submit Venue Form
  • Subscribe
  • Terms and Conditions
  • Venue Dashboard
  • Venue Dashboard
  • About Us
  • Contact Us
The Pharma Data

  • News
  • Press Releases
  • Business
  • TECHNOLOGY
  • Research
  • Regulatory
  • Events and Conferences
The Pharma Data
  • Regulatory

Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial

  • The Pharma Data
  • July 2, 2026

Genentech Reports Positive Phase III Krascendo 1 Results Demonstrating Divarasib Improves Survival in Previously Treated KRAS G12C Non-Small Cell Lung Cancer Genentech, a member of the Roche Group, has announced…

Read MoreGenentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial
  • INDUSTRY UPDATES

VIVAZEN® Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine

  • The Pharma Data
  • July 2, 2026

VIVAZEN Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine, Reinforces Commitment to Safe Botanical Wellness and Consumer Transparency VIVAZEN®, a leading botanical wellness company in the United States, has welcomed the recent…

Read MoreVIVAZEN® Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine
  • Regulatory

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer

  • The Pharma Data
  • July 2, 2026

Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer to Drive Global Growth and Strengthen Biologics CDMO Capabilities Rezon Bio, a science-driven European contract development and manufacturing organization (CDMO)…

Read MoreRezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer
  • News

Caidya and Simbec-Orion Announce Strategic Combination

  • The Pharma Data
  • July 2, 2026

Caidya and Simbec-Orion Combine to Create Global Specialty CRO Platform Spanning Early-Phase Research Through Late-Stage Clinical Development Caidya has announced a strategic combination with Simbec-Orion, marking a significant step in…

Read MoreCaidya and Simbec-Orion Announce Strategic Combination
  • Press Releases

Azalea Vision Secures EIC Accelerator Funding for Smart Contact Lens

  • The Pharma Data
  • July 2, 2026

Azalea Vision Secures Up to €7.5 Million from European Innovation Council to Advance Smart Contact Lens Platform Toward Clinical Development Belgian health technology innovator Azalea Vision has secured a major…

Read MoreAzalea Vision Secures EIC Accelerator Funding for Smart Contact Lens
  • Research

SC Therapeutics Initiates REACH2 Clinical Trial in Refractory Chronic Cough

  • The Pharma Data
  • July 2, 2026

SC Therapeutics Launches REACH2 Clinical Trial to Evaluate Novel Disease-Modifying Therapy for Refractory Chronic Cough SC Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative therapies that target mechano-sensitive ion…

Read MoreSC Therapeutics Initiates REACH2 Clinical Trial in Refractory Chronic Cough
  • INDUSTRY UPDATES

HeartBeam Completes Enrollment for Heart Attack Detection Pilot Study

  • The Pharma Data
  • July 2, 2026

HeartBeam Completes Patient Enrollment Ahead of Schedule in ALIGN-ACS Pilot Study for Heart Attack Detection HeartBeam, Inc., a medical technology company focused on advancing cardiovascular diagnostics through innovative electrocardiogram (ECG)…

Read MoreHeartBeam Completes Enrollment for Heart Attack Detection Pilot Study
  • Press Releases

Colossal Foundation Partners with University of Tasmania to Combat Devil Facial Tumour Disease

  • The Pharma Data
  • July 2, 2026

Colossal Foundation and University of Tasmania Launch Multi-Pronged Initiative to Combat Deadly Tasmanian Devil Facial Tumour Disease The Colossal Foundation, the nonprofit conservation organization established by Colossal Biosciences, has announced…

Read MoreColossal Foundation Partners with University of Tasmania to Combat Devil Facial Tumour Disease
  • News

FNIH Launches Music as Medicine Neuroscience Initiative

  • The Pharma Data
  • July 2, 2026

FNIH and Leading Advocates Launch Music as Medicine Neuroscience Initiative The Foundation for the National Institutes of Health (FNIH) has announced the launch of the Music as Medicine Neuroscience Research…

Read MoreFNIH Launches Music as Medicine Neuroscience Initiative
  • Research

CorVista Health Receives AMA Category III CPT® Code for AI Cardiopulmonary Analysis

  • The Pharma Data
  • July 2, 2026

CorVista Health Receives New AMA Category III CPT Code for AI-Powered Cardiovascular Diagnostic Technology CorVista Health has announced that the American Medical Association (AMA) has approved a new Category III…

Read MoreCorVista Health Receives AMA Category III CPT® Code for AI Cardiopulmonary Analysis
Croma-Pharma
  • RegulatoryNews

Croma-Pharma Wins FDA Approval for Obagi saypha® ChIQ™ in the U.S.

  • The Pharma Data
  • July 1, 2026

Croma-Pharma Secures FDA Approval for Obagi saypha® ChIQ™ to Expand Facial Aesthetic Treatment Options in the U.S. Croma-Pharma has reached another significant milestone in its global growth strategy with the…

Read MoreCroma-Pharma Wins FDA Approval for Obagi saypha® ChIQ™ in the U.S.
Hengrui
  • Regulatory

Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment

  • The Pharma Data
  • July 1, 2026

Hengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment Hengrui Pharma and Novaliq GmbH have announced that China’s National Medical Products Administration (NMPA) has approved Heng Yi® (0.1%…

Read MoreHengrui’s Heng Yi® Approved in China for Dry Eye Disease Treatment
Next
Global Clinical Trial Supply Forum 2026 I Frankfurt, Germany

About

The Pharma Data is an Information-Centric Website focused mainly on the Pharmaceutical Industry Online It is a B2B Platform mainly focused on the latest Pharmaceutical News, Press releases, Industry-related updates, Events, and Conferences. With The Pharma Data, you can get all the information that happening in the Pharmaceutical industry.

Advertise With Us: marketing@thepharmadata.com

Latest Posts

  • Genentech’s Divarasib Outperforms Approved KRAS G12C Inhibitors in Phase III NSCLC Trial
  • VIVAZEN® Welcomes DEA Scheduling of Synthetic 7-Hydroxymitragynine
  • Rezon Bio Appoints Dr. Hubert Scholze as Chief Business Officer
  • About Us
  • Disclaimer
  • Privacy Policy
  • Terms and Conditions
  • Contact Us

Copyright © 2026 | The Pharma Data | Marnet Technologies Pvt Ltd | All Rights Reserved.